Research Article
Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double-Blind Randomised Placebo-Controlled Trial
Table 5
Characteristics of patients who completed the protocol.
| | Variables | Total subject (n = 50) | BCM-95 (n = 28) | Placebo (n = 22) | value |
| | Age (year) | | | | 0.18 | | Min–max | 32–64 | 32–68 | 34–64 | | | Mean (SD) | 49 (49.8) | 51.3 (9.5) | 47.5 (7.8) | |
| | Educational level (%) | | | | 0.42 | | Under elementary graduate | 16 (32%) | 10 (35.7%) | 6 (27.2%) | | | Elementary–junior high school | 22 (44%) | 10 (35.7%) | 12 (54.5%) | | | >Senior high school | 12 (24%) | 8 (28.6%) | 4 (18.3%) | |
| | Preradiation BMI (kg/m 2 ) | | | | 0.98 | | Min–max | 15.4–33.2 | 15.4–33.2 | 16.8–30.6 | | | Mean (SD) | 23.9 (4.01) | 23.9 (4.3) | 24.0 (3.6) | |
| | Parity | | | | 0.13 | | Min–max | 0–9 | 0–9 | 0–6 | | | Median (variance) | 3 (4.2) | 3 (5.8) | 3 (1.71) | |
| | Creatinine (mg/dL) | | | | 0.91 | | ≤1.2 mg/dL | 39 (78%) | 22 (78.5%) | 17 (77.2%) | | | >1.2 mg/dL | 11 (22%) | 6 (21.5%) | 5 (22.7%) | |
| | Preradiation tumor size (mm) | | | | 0.31 | | Min–max | 25–125 | 29–105 | 25–125 | | | Median (variance) | 71 (514.4) | 72 (424.7) | 70 (642.8) | | | Mean+ (SD) | 4.1 (0.34) | 4.2 (0.3) | 4.1 (0.39) | 0.29 |
| | LVSI | | | | 1 | | Positive | 0 (0%) | 0 | 0 | | | Negative | 54 (100%) | 29 (100%) | 25 (100%) | |
| | Grade | | | | 0.73 | | Mild | 8 (17%) | 5 (18.5%) | 3 (15%) | | | Moderate | 30 (63.8%) | 16 (59.2%) | 14 (70%) | | | High | 9 (19.2%) | 6 (22.3%) | 3 (15%) | |
| | Radiation dose | | | | 0.31 | | Min–max | 66–78.4 | 69–78.4 | 66–74 | | | Median (variance) | 71 (4.2) | 71 (5.5) | 71 (2.5) | |
|
|
